Bristol-Myers Squibb to Hold Investor Teleconference to Discuss ASCO Highlights

NEW YORK--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE:BMY) will host a teleconference at 8:00 a.m. EDT on Monday, June 7, 2010, to review data presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. Company executives will provide an overview of data presented at the meeting on the oncology portfolio and address inquiries from investors and analysts.

Investors and the general public are invited to listen to a live webcast of the call at: http://investor.bms.com or by dialing 913-312-0711, confirmation code: 1985004. A replay of the call will be available beginning at 11:00 a.m. EDT on June 7 through midnight EDT on June 21. The replay can be accessed at http://investor.bms.com or by dialing 402-280-9013, confirmation code: 1985004.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company committed to discovering, developing and delivering innovative medicines that help patients prevail over serious diseases. For more information, please visit www.bms.com.



CONTACT:

Bristol-Myers Squibb Company
Media:
Jennifer Fron Mauer, 609-252-6579
[email protected]
or
Investors:
John Elicker, 609-252-4611
[email protected]

KEYWORDS:   United States  North America  New York

INDUSTRY KEYWORDS:   Health  Biotechnology  Oncology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.